Sex-specific mitochondrial marker deficiencies linked to early cognitive dysfunction in Alzheimer’s disease

Plus, news about OnKure: De­ci­phera’s oth­er bid­der: Be­fore its ac­qui­si­tion by Ono Phar­ma­ceu­ti­cal, De­ci­phera had one oth­er bid­der that of­fered $19.00 per share, ac­cord­ing to

No­var­tis is re­turn­ing to Hunt­ing­ton’s dis­ease with a $1 bil­lion up­front bet, plus an­oth­er $1.9 bil­lion in biobucks, for ac­cess to a Phase 2 oral